"T1: hypointense"
"T2: hyperintense +/- hypointense central focus (target sign)"
"T1 C+: mild enhancement"
"The mode and frequency of surveillance for patients with NF1 but without diagnosed optic pathway gliomas varies depending on local preference and resources. The European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) 2023 guidelines suggest the following 8:"
"The mode and frequency of surveillance for patients with NF1 but without diagnosed optic pathway gliomas varies depending on local preference and resources. The European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) 2023 guidelines suggest the following 8:"
Expected headings
"Surveillance"
"There is variable use and some confusion about the distinction between plexiform neurofibroma and diffuse cutaneous neurofibroma, with some sources not clearly distinguishing between the two. Generally, plexiform neurofibromas are deeper lesions affecting nerves and plexus. The two may, however, co-exist 5."
"clinical assessment for plexiform neurofibromas should begin at diagnosis or birth and be carried out at every clinical visit by clinicians with NF1 expertise, using observation, palpation, and neurological examination; photography or video can be useful adjuncts to these assessments"
"Although generally benign tumours, there is a significant potential for malignant transformation, which occurs at a lifetime risk of 9-13% in patients with NF1 7,10. If complete resection is possible, then a cure can be effected; however, due to the infiltrating nature of these tumours, such a resection is usually not possible. In such cases MEK inhibitors (e.g. selumetinib) can be considered 8,9."